A single medical marker for diagnosis of methamphetamine addiction-dna methylation of SHATI/NAT8L promoter sites from patient blood

Kusui Yuka, Daisuke Nishizawa, Junko Hasegawa, Kyosuke Uno, Hajime Miyanishi, Hiroshi Ujike, Norio Ozaki, Toshiya Inada, Nakao Iwata, Ichiro Sora, Masaomi Iyo, Mitsuhiko Yamada, Naoki Kondo, Moo Jun Won, Nobuya Naruse, Kumi Uehara-Aoyama, Kazutaka Ikeda, Atsumi Nitta

研究成果: Article

抜粋

Background: Methamphetamine (METH) is one of the most widely distributed psychostimulants worldwide. Despite active counter measures taken by different countries, neither overall usage of METH nor the frequency of repeat users has reduced over the past decade. METH induces abuse and dependence as it acts on the central nervous system and temporarily stimulates the brain. The recidivism rate for abuse of stimulants in Japan is very high and therefore prevention of repeated usage is paramount. However, we lack information about the relationship between METH users and genomic changes in humans in Japan, which would provide important information to aid such efforts. Objective: Shati/Nat8l is a METH-inducible molecule and its overexpression has protective effects on the brain upon METH usage. Here we investigated the effect of METH usage on DNA methylation rates at the promoter site of SHATI/NAT8L. We used DNA samples from human METH users, who are usually difficult to recruit in Japan. Methods: We measured DNA methylation at SHATI/NAT8L promoter sites by pyrosequencing method using 193 samples of METH users and 60 samples of healthy subjects. In this method, DNA methylation is measured by utilizing the property that only non-methylated cytosine changes to urasil after bisulfite conversion. Results: We found that the rate of DNA methylation at six CpG islands of SHATI/NAT8L promoter sites is significantly higher in METH users when compared to healthy subjects. Conclusion: These results suggest that the DNA methylation rate of SHATI/NAT8L promotor regions offers a new diagnostic method for METH usage.

元の言語English
ページ(範囲)260-264
ページ数5
ジャーナルCurrent Pharmaceutical Design
26
発行部数2
DOI
出版物ステータスPublished - 01-01-2019

    フィンガープリント

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Drug Discovery

これを引用

Yuka, K., Nishizawa, D., Hasegawa, J., Uno, K., Miyanishi, H., Ujike, H., Ozaki, N., Inada, T., Iwata, N., Sora, I., Iyo, M., Yamada, M., Kondo, N., Won, M. J., Naruse, N., Uehara-Aoyama, K., Ikeda, K., & Nitta, A. (2019). A single medical marker for diagnosis of methamphetamine addiction-dna methylation of SHATI/NAT8L promoter sites from patient blood. Current Pharmaceutical Design, 26(2), 260-264. https://doi.org/10.2174/1381612826666200110111703